ryz101
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 24, 2022 (NCT05477576)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
- Payload
- 225-actinium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07150806 | Phase 1/Phase 2 (Phase 2) | Nov 13, 2025 | Ohio State University, RayzeBio, Inc. |
| NCT06732505 | Phase 1 | Jan 1, 2025 | Peking University, Sinotau Pharmaceutical Group |
| NCT06411301 | Phase 1 | Oct 31, 2024 | Free University of Brussels, RayzeBio, Inc. |
| NCT06590857 | Phase 1/Phase 2 (Phase 2) | Jul 19, 2024 | RayzeBio, Inc. |
| NCT05595460 | Phase 1 | Oct 10, 2022 | RayzeBio, Inc. |
| NCT05477576 | Phase 1/Phase 2 (Phase 2) | Mar 24, 2022 | RayzeBio, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RayzeBio, Inc. | For profit | 5 | 3 | 2 | 2022 |
| Free University of Brussels | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Sinotau Pharmaceutical Group | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1